Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors

AUTOR(ES)

Kelly, S

FONTE

Nature Publishing Group

RESUMO

There is good evidence to suggest that dose intensity is important when considering the effectiveness of adjuvant chemotherapy in patients with breast cancer. However, the development of chemotherapy-induced febrile neutropenia can lead to reduction in dose intensity and other treatment modifications, which may negatively affect patient outcomes. Febrile neutropenia can be prevented by the use of primary prophylactic treatment, notably with granulocyte colony-stimulating factors. This practice is supported by international guidelines, all of which recommend that primary prophylaxis with granulocyte colony-stimulating factors should be used with chemotherapy where the risk of febrile neutropenia is 20% or greater.

Documentos Relacionados

• Prevention of febrile neutropenia: use of prophylactic antibiotics
• Chronic neutropenia. A new canine model induced by human granulocyte colony-stimulating factor.
• Neonatal sepsis with neutropenia: granulocyte-colony stimulating factor (G-CSF)
• Increased granulocyte colony-stimulating factor responsiveness but normal resting granulopoiesis in mice carrying a targeted granulocyte colony-stimulating factor receptor mutation derived from a patient with severe congenital neutropenia.
• Abnormal responses of myeloid progenitor cells to granulocyte-macrophage colony-stimulating factor in human cyclic neutropenia.